Somewhat Favorable Press Coverage Somewhat Unlikely to Affect Chembio Diagnostics (CEMI) Stock Price
Media coverage about Chembio Diagnostics (NASDAQ:CEMI) has been trending somewhat positive recently, according to Accern Sentiment Analysis. The research group identifies negative and positive press coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Chembio Diagnostics earned a daily sentiment score of 0.14 on Accern’s scale. Accern also assigned media headlines about the company an impact score of 46.7542669042639 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
Here are some of the media headlines that may have impacted Accern’s rankings:
- BRIEF-Chembio Diagnostics says CFO Richard Larkin to retire by Dec 31 (reuters.com)
- Chembio Diagnostics (CEMI) CFO to Retire (streetinsider.com)
- Chembio Diagnostics Announces Retirement of Chief Financial Officer (4-traders.com)
- Chembio Diagnostics Announces Retirement of Chief Financial Officer (finance.yahoo.com)
Separately, ValuEngine raised Chembio Diagnostics from a “strong sell” rating to a “sell” rating in a report on Friday, June 2nd.
Chembio Diagnostics (NASDAQ CEMI) traded up 1.65% during mid-day trading on Friday, reaching $6.15. The company’s stock had a trading volume of 31,251 shares. Chembio Diagnostics has a 1-year low of $5.05 and a 1-year high of $7.47. The company’s market capitalization is $75.70 million. The firm has a 50 day moving average price of $6.24 and a 200-day moving average price of $6.07.
Chembio Diagnostics (NASDAQ:CEMI) last announced its earnings results on Wednesday, August 9th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.16) by $0.02. The company had revenue of $2.89 million for the quarter, compared to analyst estimates of $4.96 million. Chembio Diagnostics had a negative return on equity of 48.79% and a negative net margin of 51.99%. On average, equities analysts predict that Chembio Diagnostics will post ($0.52) EPS for the current fiscal year.
In related news, insider Norman H. Pessin bought 36,250 shares of the business’s stock in a transaction dated Wednesday, June 28th. The shares were bought at an average cost of $5.48 per share, with a total value of $198,650.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 5.56% of the stock is owned by insiders.
TRADEMARK VIOLATION WARNING: This piece was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece on another website, it was illegally stolen and reposted in violation of US & international trademark and copyright law. The correct version of this piece can be read at https://www.thecerbatgem.com/2017/08/20/somewhat-favorable-press-coverage-somewhat-unlikely-to-affect-chembio-diagnostics-cemi-stock-price.html.
Chembio Diagnostics Company Profile
Chembio Diagnostics, Inc (Chembio), and its subsidiary, Chembio Diagnostic Systems, Inc, develop, manufacture, market and license rapid point-of-care diagnostic tests (POCTs) that detect infectious diseases. The Company’s products available are rapid tests for the detection of human immunodeficiency virus (HIV) 1/2 antibodies, and a multiplex rapid test for the detection of HIV and Syphilis antibodies.
Receive News & Stock Ratings for Chembio Diagnostics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chembio Diagnostics Inc. and related stocks with our FREE daily email newsletter.